ROC analysis revealed that differences in PDGFA and TGFB2 gene expression were sufficient to differentiate between IM-ILD and IPF patients, indicating that they act as accurate diagnostic biomarkers for IM-ILD (AUC: 0.6179, p = 0.0369 and 0.7064, p = 0.0003, respectively; Figure 3C, Table S1). This evidence concerns the gene TGFB2 and interstitial lung disease.